Asmiket Tablet: Each tablet contains Ketotifen Fumarate BP 1.38 mg equivalent to Ketotifen 1 mg.
Asmiket Syrup: Each 5 ml syrup contains Ketotifen Fumarate BP 1.38 mg equivalent to Ketotifen 1 mg.
Ketotifen is a nonbronchodilator anti-asthmatic drug which inhibits the effects of certain endogenous substances known to be inflammatory mediators. In addition, Ketotifen is a potent anti-allergic substance possessing a powerful and sustained noncompetitive histamine ( $H_1$ ) receptor blocking property. Ketotifen is a type of asthma medication which, when taken every day and used along with other anti-asthmatic medications, may reduce the frequency, severity and duration of asthma symptoms or attacks in patients. It may also lead to a reduction in daily requirements of other anti-asthmatic medications such as Theophyllines and $\beta_2$ -agonists, without the deterioration in pulmonary functions (FEV1, FVC and PEFR). The prophylactic activity of Ketotifen may take several weeks to become fully established. Ketotifen will not abort established attacks of asthma.
a) Route of administration: Oral (Ketotifen may be taken with or without food).
Asmiket Tablet:
Above 3 years and Adults: 1 mg twice daily (once in the morning & once in the evening). Elderly Same as adult dose or as advised by the physician.
Asmiket Syrup:
6 months to 3 years: 0.25 ml / kg body weight, twice daily (Once in the morning & once in the evening).
a) With medicine: A reversible fall in the thrombocyte count in patients receiving Ketotifen concomitantly with oral anti-diabetic agents has been observed in rare cases. So it has been suggested that this combination should therefore be avoided.
b) With food & others: Ketotifen may potentiate the effects of sedatives, hypnotics, anti-histamines and alcohol.
Overdose:
The reported features of over dosage include confusion, drowsiness, disorientation, headache, bradycardia and respiratory depression. Elimination of the drug with gastric lavage or emesis is recommended. Otherwise general supportive treatment is all that is required shall be instituted.
Pregnancy: Its safety in human pregnancy has not been established. Ketotifen should therefore be given to pregnant women only in compelling circumstances.
Lactation: Ketotifen is excreted in breast milk. Therefore mothers receiving Ketotifen should not breast-feed.
See the dose and administration.
Symptomatic and prophylactic anti-asthmatic drugs (Xanthine derivatives, $\beta_2$ -agonists, Sodium Cromoglycate, Corticosteroids) already in use should not be reduced immediately when treatment with Ketotifen is initiated. This applies especially to Systemic Corticosteroids and ACTH injections because of the possible existence of adrenocortical insufficiency in steroid-dependent patients. During the first day of treatment with Ketotifen, reactions may be impaired and patients should be warned not to take charge of vehicle or machinery until the effect of Ketotifen treatment on the individual is known.
Store below 30°C. Protect from light and moisture. Keep all medicines out of reach of children.